Skip to content
Calculator

GHK-Cu, BPC-157, TB-500 and KPV blend (80 mg)

This is the largest of the common peptide blends: four peptides freeze-dried together in one 80 mg vial, most of it GHK-Cu. Each ingredient has been studied a little on its own, mostly in animals or on skin. The four together have never been studied at all. Sellers often call it 'KLOW'; the name is a market nickname, not an ingredient list, and the same name can mean different contents.

As sold, one vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. Statuses as of October 3, 2026. Reviewed by the Grey Peptides Editorial Board. Nothing here is a recommendation or a dose, and no seller is named or linked.

Each component at a glance

From our encyclopedia and FDA's July 2026 Pharmacy Compounding Advisory Committee record. Evidence grades follow the rubric on our methodology page.

ComponentEvidenceFDA statusPCAC, July 2026WADA 2026WADA 2027Interactions
GHK-CuMediumResearch ChemicalNot voted onProhibited under S0 (not named)Prohibited under S0 (not named)None found in the literature
BPC-157LowResearch ChemicalRecommended (8-6, July 23, 2026); FDA has not actedProhibited (S0)Prohibited (S0)Partly reviewed
TB-500LowResearch ChemicalRecommended (8-6, July 23, 2026); FDA has not actedProhibited (S2.3)Prohibited (S2.3)Partly reviewed
KPVLowResearch ChemicalRecommended (8-6, July 23, 2026); FDA has not actedProhibited under S0 (not named)Prohibited under S0 (not named)None found in the literature

What one vial contains: the ratio arithmetic

The vial holds 80 mg in total. Whatever volume of water is added and however much is drawn, every draw carries the components in the same proportions. The table expresses each as a share of the vial, as a multiple of the smallest component (BPC-157), and as a concentration if the whole vial were dissolved in 2 mL or 3 mL of water. These are arithmetic illustrations of what is in the vial, not suggested volumes or doses.

ComponentIn the vialShare× BPC-157In 2 mLIn 3 mL
GHK-Cu50 mg62.5%525 mg/mL16.67 mg/mL
BPC-15710 mg12.5%15 mg/mL3.33 mg/mL
TB-50010 mg12.5%15 mg/mL3.33 mg/mL
KPV10 mg12.5%15 mg/mL3.33 mg/mL

The Blend & Stack Calculator runs the same arithmetic for any volume and draw, with this composition as a preset (GHK-Cu, BPC-157, TB-500 and KPV, 80 mg (50/10/10/10)).

What is in the vial, as sold

Listings for this blend generally state 50 mg of GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV, which is the composition our calculator models. The Name Decoder's review of listings found at least one that reverses the GHK-Cu and BPC-157 amounts, so the label on any particular vial is the first thing to check. A blend's stated composition is a seller's claim: nothing requires the contents of an unregulated vial to match it, and a certificate of analysis that quantifies only one of the four peptides says nothing about the other three.

GHK-Cu makes up 62.5% of the vial by weight. That proportion shapes everything else on this page, because in a fixed-ratio blend the largest component sets the exposure to it whenever any amount of the others is drawn.

What each ingredient's evidence shows

BPC-157 is a 15-amino-acid fragment of a protein in human gastric juice, studied mostly in rats for tissue repair. The human record is two small reports: a 2025 pilot that gave intravenous BPC-157 to two people and found it tolerated, with no change in the markers tested1, and a 2021 chart review of knee injections at one clinic with no control group2.

TB-500 is a synthetic fragment modelled on thymosin beta-4. No human trial has tested TB-500 as sold; its one published human use is an uncontrolled 2026 report of three dental patients given it with BPC-157 and three other drugs3. The human studies are of the parent protein: an intravenous safety study in healthy volunteers4 and a European trial of thymosin beta-4 applied to venous leg ulcers5. Neither says anything direct about injecting TB-500.

GHK-Cu is a copper complex of a three-amino-acid peptide, and its human evidence is about skin. In a small trial after laser resurfacing, patients rated their skin quality higher with topical GHK-Cu, although investigator-rated outcomes did not differ between groups6. No human study on our entry tested an injection, which is how blends are used.

KPV is lysine-proline-valine, the last three amino acids of alpha-MSH. Its evidence comes from mice: it reduced inflammation in chemically induced colitis7 and in other mouse models of inflammatory bowel disease8. It has not been tested in people.

Has anyone studied the mix?

No. The only reports of giving any combination of these ingredients involve two of them, BPC-157 and TB-500 or a relative of it. A 2026 rat study cut and repaired the Achilles tendon in 32 rats, then gave BPC-157, TB-500, both, or nothing for four weeks; only the TB-500 group showed a significant gain in tendon strength, the combination scored better on one tissue-structure scale, and BPC-157 alone did not reach significance on the overall scores9. The 2021 knee chart review included four patients who had separate injections of BPC-157 and what the paper calls thymosin-beta-4 (TB4)2, and a 2026 dental case series gave three patients BPC-157 and TB-500 with three other drugs3. None tested GHK-Cu or KPV, and none used a fixed-ratio vial.

That leaves the questions a combination study would answer with no answer at all: whether the four interact with each other, whether one changes how another is absorbed or cleared, whether side effects add up, and whether the peptides stay stable when dissolved and stored together. We found no published data on the stability of these peptides mixed in one vial.

The fixed-ratio problem, for this blend

With five times as much GHK-Cu as each of the other three, any amount drawn to deliver a chosen quantity of BPC-157 also delivers five times that quantity of GHK-Cu, plus equal amounts of TB-500 and KPV. There is no way to take more of one ingredient without taking more of all four, or to stop one while continuing the others. If a reaction happens, a four-way blend makes it impossible to tell which ingredient caused it. These are properties of the vial, not of any particular use, and they are why separate, labelled products are easier to reason about than a mix.

Regulatory status in the United States

None of the four is approved by FDA for any use. In July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157, TB-500 and KPV to the list of substances pharmacies may use in compounding, against the advice of FDA's own reviewers, as reported (FDA has posted no tallies)1011. A recommendation is not a decision: as of October 3, 2026, FDA had not acted on it, and until it does, pharmacies cannot lawfully compound them. Injectable GHK-Cu cannot be compounded either: FDA's 503A category list (Updated May 14, 2026) says GHK-Cu "was removed from category 1 on April 22, 2026, because the nominations for GHK-Cu were withdrawn by the nominators"; on May 5, 2026 one nominator clarified that it meant to withdraw only its injectable nomination, so only non-injectable GHK-Cu went back into Category 1, and FDA intends to consult its compounding advisory committee on GHK-Cu before the end of February 202712. Even if every vote were adopted, compounding rules apply to individual substances for individual patients, not to a pre-mixed four-peptide vial sold online. Our regulatory tracker follows each substance.

On October 30, 2026, HHS, FDA's parent department, published a non-binding draft policy saying it will not take enforcement action against 503A pharmacies that compound BPC-157, TB-500 and KPV under set conditions13. It does not add any of them to the 503A Bulks List or Category 1 and does not cover research-use-only sales, and it allows only one of its six peptides in each compounded product, so a pre-mixed blend like this one is outside it (our fact check).

For tested athletes

All four ingredients are prohibited at all times under the World Anti-Doping Code. BPC-157 is named under S0, non-approved substances, and TB-500 under S214. GHK-Cu and KPV are not named, but as substances with no current approval for human therapeutic use they fall under the S0 catch-all, which covers any pharmacological substance not addressed elsewhere on the List and not approved for human use14. A positive test for any one of them is an anti-doping rule violation, and athletes are strictly liable for what is in a product they take, including an ingredient they did not know was there.

Questions to ask about any vial like this

The Name Decoder's questions for this blend are the ones that matter most. What are the milligrams of each of the four, and do they match the label? Does the certificate of analysis quantify all four peptides by name, with purity for each, or only one? Is the testing laboratory identified, and is the report tied to the batch in hand? Our COA Decoder explains what a genuine report contains and the red flags of a fake one, and our guide to spotting a fake certificate walks through a worked example.

The deeper question is whether a mix is needed at all. A blend combines four ingredients with different, thin evidence bases into one product that cannot be adjusted. Anyone considering it should discuss it with a clinician who knows what they are taking.

Sources

  1. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31. PubMed 40131143 ↗
  2. Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27. PubMed 34324435 ↗
  3. Froum, S., et al. (2026). Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 7. PubMed 42876687 ↗
  4. Ruff, D., et al. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci, 1194. PubMed 20536472 ↗
  5. Guarnera, G., et al. (2007). Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci, 1112. PubMed 17495250 ↗
  6. Miller, T. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8. PubMed 16847171 ↗
  7. Dalmasso, G., et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134. PubMed 18061177 ↗
  8. Kannengiesser, K., et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis, 14. PubMed 18092346 ↗
  9. Biçer, O., et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 37. PubMed 42542926 ↗
  10. McDermott (law firm). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): tallies for all seven. Read October 27, 2026; FDA has posted no minutes or tallies. Other reports agree on every tally except epitalon's 'no' count (7-4-1 here and in the FDA Law Blog; 7-5-1 in RAPS Regulatory Focus). Cited without a link.
  11. U.S. Food and Drug Administration. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee: briefing documents for BPC-157, KPV and TB-500; no minutes or vote tallies posted. Page current as of August 6, 2026; re-read October 3 and October 27, 2026. Source ↗
  12. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (GHK-Cu removed from Category 1 on April 22, 2026 after its nominations were withdrawn; non-injectable routes added back after a May 5, 2026 clarification). Updated May 14, 2026; re-read October 27, 2026. Source ↗
  13. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496; non-binding, labelled a draft. Read November 4, 2026. Source ↗
  14. World Anti-Doping Agency. The 2026 Prohibited List (S0 non-approved substances; S2 peptide hormones, growth factors and related substances), in force January 1 to December 31, 2026; the 2027 List keeps the same statuses for these four. Read in full July 16, 2026. Source ↗

Related: the blends and stacks hub, the Name Decoder, the COA Decoder and the Interaction Matrix. Last updated October 3, 2026.